Short Interest in NuCana plc (NASDAQ:NCNA) Declines By 15.7%

NuCana plc (NASDAQ:NCNA) was the recipient of a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 121,700 shares, a decline of 15.7% from the December 31st total of 144,300 shares. Currently, 3.3% of the company’s shares are sold short. Based on an average trading volume of 149,300 shares, the days-to-cover ratio is currently 0.8 days.

NuCana Trading Down 4.9 %

Shares of NCNA traded down $0.05 during mid-day trading on Monday, reaching $0.97. The company’s stock had a trading volume of 65,337 shares, compared to its average volume of 96,745. The stock has a market cap of $2.56 million, a PE ratio of -0.09 and a beta of 0.97. NuCana has a 52 week low of $0.85 and a 52 week high of $19.41. The company’s fifty day moving average price is $1.21 and its two-hundred day moving average price is $2.43.

NuCana (NASDAQ:NCNA) last posted its quarterly earnings results on Monday, November 25th. The company reported ($2.28) EPS for the quarter, beating analysts’ consensus estimates of ($3.49) by $1.21. Research analysts anticipate that NuCana will post -12.86 EPS for the current year.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.